2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
Schnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.Peer-Reviewed Original ResearchConceptsPatient-perceived benefitsAdverse eventsBrief Pain Inventory-Short FormAromatase Inhibitor–Associated ArthralgiaDuloxetine-treated patientsOriginal primary outcomeDouble-blind trialLow-grade toxicityEffect of duloxetineSubgroup of patientsAverage painComparable patientsAppropriate patientsPrimary outcomeMusculoskeletal symptomsBreast cancerPlaceboDuloxetineSide effectsFunctional assessmentPatientsSecondary analysisFavorable effectTreatmentPerceptions of benefits
2017
Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm
Reinbolt R, Sonis S, Timmers C, Fernández‐Martínez J, Cernea A, de Andrés‐Galiana E, Hashemi S, Miller K, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm. Cancer Medicine 2017, 7: 240-253. PMID: 29168353, PMCID: PMC5773952, DOI: 10.1002/cam4.1256.Peer-Reviewed Original Research